Literature DB >> 21841064

Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease.

Susan L Furth1, Alison G Abraham, Judith Jerry-Fluker, George J Schwartz, Mark Benfield, Frederick Kaskel, Craig Wong, Robert H Mak, Marva Moxey-Mims, Bradley A Warady.   

Abstract

BACKGROUND AND OBJECTIVES: Metabolic abnormalities and cardiovascular disease (CVD) risk factors have rarely been systematically assessed in children with chronic kidney disease (CKD). We examined the prevalence of various CKD sequelae across the GFR spectrum. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data were used from 586 children participating in the Chronic Kidney Disease in Children (CKiD) study (United States and Canada) with GFR measured by iohexol plasma disappearance. Laboratory values and CVD risk factors were compared across GFR categories and with an age-, gender-, and race-matched community sample.
RESULTS: CKiD participants were 62% male, 66% Caucasian, 23% African American, and 15% Hispanic with a median age of 11 years and a median GFR of 44 ml/min per 1.73 m(2). Compared with those with a GFR ≥ 50 ml/min per 1.73 m(2), having a GFR < 30 ml/min per 1.73 m(2) was associated with a three-fold higher risk of acidosis and growth failure and a four- to five-fold higher risk of anemia and elevated potassium and phosphate. Median GFR change was -4.3 ml/min per 1.73 m(2) and -1.5 ml/min per 1.73 m(2) per year in children with glomerular and nonglomerular diagnoses, respectively. Despite medication and access to nephrology care, uncontrolled systolic hypertension was present in 14%, and 16% had left ventricular hypertrophy. Children with CKD frequently were also shorter and had lower birth weight, on average, compared with norms.
CONCLUSIONS: Growth failure, metabolic abnormalities, and CVD risk factors are present at GFR >50 ml/min per 1.73 m(2) in children with CKD and, despite therapy, increase in prevalence two- to four-fold with decreasing GFR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841064      PMCID: PMC3358991          DOI: 10.2215/CJN.07100810

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  26 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  US Renal Data System 2010 Annual Data Report.

Authors:  Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2011-01       Impact factor: 8.860

3.  Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.

Authors:  R B Devereux; N Reichek
Journal:  Circulation       Date:  1977-04       Impact factor: 29.690

4.  Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects.

Authors:  M Soergel; M Kirschstein; C Busch; T Danne; J Gellermann; R Holl; F Krull; H Reichert; G S Reusz; W Rascher
Journal:  J Pediatr       Date:  1997-02       Impact factor: 4.406

5.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

6.  Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures.

Authors: 
Journal:  Vital Health Stat 1       Date:  1994-07

7.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

8.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight.

Authors:  G de Simone; S R Daniels; R B Devereux; R A Meyer; M J Roman; O de Divitiis; M H Alderman
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

9.  Cardiovascular disease in pediatric chronic dialysis patients.

Authors:  Blanche M Chavers; Shuling Li; Allan J Collins; Charles A Herzog
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

10.  Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.

Authors:  J Craig Longenecker; Josef Coresh; Neil R Powe; Andrew S Levey; Nancy E Fink; Alice Martin; Michael J Klag
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

View more
  64 in total

1.  Treatment of infant formula with patiromer dose dependently decreases potassium concentration.

Authors:  Neil J Paloian; Barbara Bowman; Sharon M Bartosh
Journal:  Pediatr Nephrol       Date:  2019-04-08       Impact factor: 3.714

2.  Estimating Time to ESRD in Children With CKD.

Authors:  Susan L Furth; Chris Pierce; Wun Fung Hui; Colin A White; Craig S Wong; Franz Schaefer; Elke Wühl; Alison G Abraham; Bradley A Warady
Journal:  Am J Kidney Dis       Date:  2018-04-10       Impact factor: 8.860

3.  Assessing longitudinal trends in cardiac function among pediatric patients with chronic kidney disease.

Authors:  Ylva Tranæus Lindblad; Georgios Vavilis; Jonas Axelsson; Maria Herthelius; Peter Bárány
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

4.  A predictive model of progression of CKD to ESRD in a predialysis pediatric interdisciplinary program.

Authors:  Debora C Cerqueira; Cristina M Soares; Vanessa R Silva; Juliana O Magalhães; Isabella P Barcelos; Mariana G Duarte; Sergio V Pinheiro; Enrico A Colosimo; Ana Cristina Simões e Silva; Eduardo A Oliveira
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

5.  End-stage kidney disease after pediatric nonrenal solid organ transplantation.

Authors:  Rebecca L Ruebner; Peter P Reese; Michelle R Denburg; Peter L Abt; Susan L Furth
Journal:  Pediatrics       Date:  2013-10-14       Impact factor: 7.124

Review 6.  Chronic Kidney Disease and Dietary Measures to Improve Outcomes.

Authors:  Oleh M Akchurin
Journal:  Pediatr Clin North Am       Date:  2019-02       Impact factor: 3.278

Review 7.  Cardiovascular disease in children with chronic kidney disease.

Authors:  Mark M Mitsnefes
Journal:  J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 10.121

8.  Contribution of symmetric dimethylarginine to GFR decline in pediatric chronic kidney disease.

Authors:  Ellen R Brooks; Shannon Haymond; Alfred Rademaker; Christopher Pierce; Irene Helenowski; Rod Passman; Faye Vicente; Bradley A Warady; Susan L Furth; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

9.  Low Serum Bicarbonate and CKD Progression in Children.

Authors:  Denver D Brown; Jennifer Roem; Derek K Ng; Kimberly J Reidy; Juhi Kumar; Matthew K Abramowitz; Robert H Mak; Susan L Furth; George J Schwartz; Bradley A Warady; Frederick J Kaskel; Michal L Melamed
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-28       Impact factor: 8.237

10.  Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Authors:  Anthony A Portale; Myles S Wolf; Shari Messinger; Farzana Perwad; Harald Jüppner; Bradley A Warady; Susan L Furth; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-25       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.